Neoadjuvant and adjuvant chemotherapy for high-risk localized prostate cancer

被引：1
作者：
Nakabayashi M. [1 ]
Oh W.K. [1 ]
机构：
[1] Lank Ctr. for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115
来源：
Current Treatment Options in Oncology | 2004年 / 5卷 / 5期
关键词：
Prostate Cancer; Radical Prostatectomy; Lycopene; Gleason Score; Androgen Deprivation Therapy;
D O I：
10.1007/s11864-004-0025-3
中图分类号：
学科分类号：
摘要：
The optimal treatment strategy for patients with high-risk localized prostate cancer remains unknown. Definitive local treatments such as radical prostatectomy and external beam radiotherapy cure only a minority of these patients. Recent efforts have been made to reduce the risk of recurrence and delay progression to symptomatic hormone-refractory disease by using chemotherapy before, during, or after definitive local therapy. Chemotherapy is an effective modality in the treatment of hormone-refractory prostate cancer. Studies have established its role in the palliation of symptoms in patients with hormone-refractory disease, though a survival benefit remains to be demonstrated. Prospective randomized trials are underway to test the hypothesis that neoadjuvant and adjuvant chemotherapy may improve survival rate in patients with high-risk localized prostate cancer. The data currently available from nonrandomized trials have not yet established the exact role of neoadjuvant and adjuvant chemotherapy and its potential impact on survival. However, preliminary data suggest that chemotherapy, when administered in concert with definitive local therapy, may be promising in patients with locally advanced prostate cancer. Randomized clinical trials are ongoing to see if neoadjuvant and adjuvant chemotherapy will translate into an improved clinical benefit for the patient, and participation by patients is paramount. We review the recent literature regarding the use of neoadjuvant and adjuvant chemotherapy in patients with locally advanced prostate cancer. Copyright © 2004 by Current Science Inc.
引用
收藏
页码：349 / 355
页数：6
相关论文
共 31 条
  • [1] Kupelian P.A., Elshaikh M., Reddy C.A., Et al., Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: A large single-institution experience with radical prostatectomy and external-beam radiotherapy, J. Clin. Oncol., 20, pp. 3376-3385, (2002)
  • [2] D'Amico A.V., Whittington R., Malkowicz S.B., Et al., Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer, JAMA, 280, pp. 969-974, (1998)
  • [3] Pathak S.K., Sharma R.A., Mellon J.K., Chemoprevention of prostate cancer by diet-derived antioxidant agents and hormonal manipulation, Int. J. Oncol., 22, 1, pp. 5-13, (2003)
  • [4] Kucuk O., Sarkar F.H., Sakr W., Et al., Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy, Cancer Epidemiol. Biomarkers Prev., 10, 8, pp. 861-868, (2001)
  • [5] Bosland M.C., Kato I., Melamed J., Et al., Chemoprevention trials in men with prostate-specific antigen failure or at high risk for recurrence after radical prostatectomy: Application to efficacy assessment of soy protein, Urology, 57, SUPPL. 4A, pp. 202-204, (2001)
  • [6] DeVere White R.W., Hackman R.M., Soares S.E., Et al., Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer, Urology, 63, pp. 259-263, (2004)
  • [7] Moyad M.A., Carroll P.R., Lifestyle recommendations to prevent prostate cancer, part I: Time to redirect our attention?, Urol. Clin. North. Am., 31, 2, pp. 289-300, (2004)
  • [8] Moyad M.A., Carroll P.R., Lifestyle recommendations to prevent prostate cancer, part II: Time to redirect our attention?, Urol. Clin. North. Am., 31, 2, pp. 301-311, (2004)
  • [9] Oh W.K., Kantoff P.W., Treatment of locally advanced prostate cancer. Is chemotherapy the next step?, J. Clin. Oncol., 17, pp. 3664-3675, (1999)
  • [10] D'Amico A.V., Moul J., Carroll P.R., Sun L., Lubeck D., Chen M.H., Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era, J. Clin. Oncol., 21, 11, pp. 2163-2172, (2003)
1234